Combination Treatment of Stereotactic Body Radiation Therapy and Immature Dendritic Cell Vaccination for Augmentation of Local and Systemic Effects / Journal of the Korean Cancer Association, 대한암학회지

PURPOSE: The purpose of this study was to investigate the efficacy of stereotactic body radiation therapy (SBRT) as a tumor-associated antigen (TAA) presentation method for dendritic cell (DC) sensitization and evaluate its effect in combination with immunotherapy using an intratumoral injection of immature DCs (iDCs). MATERIALS AND METHODS: CT-26 colon carcinoma cell was used as a cancer cell line. Annexin V staining and phagocytosis assays were performed to determine the appropriate radiation dose and incubation time to generate TAAs. BALB/c mice were used for in vivo experiments. Cancer cells were injected into the right legs and left flanks to generate primary and metastatic tumors, respectively. The mice were subjected to radiation therapy (RT) alone, intradermal injection of electroporated DCs alone, or RT in combination with iDC intratumoral injection (RT/iDC). Tumor growth measurement and survival rate analysis were performed. Enzyme-linked immunospot and cytotoxicity assays were performed to observe the effect of different treatments on the immune system. RESULTS: Annexin V staining and phagocytosis assays showed that 15 Gy radiation dose and 48 hours of incubation was appropriate for subsequent experiments. Maximum DC sensitization and T-cell stimulation was observed with RT as compared to other TAA preparation methods. In vivo assays revealed statistically significant delay in the growth of both primary and metastatic tumors in the RT/iDC group. The overall survival rate was the highest in the RT/iDC group. CONCLUSION: The combination of SBRT and iDC vaccination may enhance treatment effects. Clinical trials and further studies are warranted in the future.

T-cell receptor-engineered T cells for cancer treatment: current status and future directions

T-cell receptor (TCR)-engineered T cells are a novel option for adoptive cell therapy used for the treatment of several advanced forms of cancer. Work using TCR-engineered T cells began more than two decades ago, with numerous preclinical studies showing that such cells could mediate tumor lysis and eradication. The success of these trials provided the foundation for clinical trials, including recent clinical successes using TCR-engineered T cells to target New York esophageal squamous cell carcinoma (NY-ESO-1). These successes demonstrate the potential of this approach to treat cancer. In this review, we provide a perspective on the current and future applications of TCR-engineered T cells for the treatment of cancer. Our summary focuses on TCR activation and both pre-clinical and clinical applications of TCR-engineered T cells. We also discuss how to enhance the function of TCR-engineered T cells and prolong their longevity in the tumor microenvironment.

Clinical significance of interleukin -17,18,32 and lung adenocarcinoma antigen in evaluating the severity of acute exacerbations of COPD / 中国基层医药

Objective To investigate the correlation between the expression of IL -17,18,32 as well as the lung adenocarcinoma antigen KL -6 and the severity of patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).Methods Totally 120 AECOPD patients treated in our hospital (Zhejiang Rongjun Hospital) form Jan 2014 to Jan 2016 were selected.Among them,the condition of 50 cases got controlled after treatment(group A),while other 70 cases did not get controlled(group B).At the same time,26 healthy people were selected as control group.The expression levels of IL -17,18,32 and KL -6 in the blood of there groups were detected by ELISA.Results The IL -17,18,32,KL -6 levels of group A were (49.07 ±17.22)pg/mL,(156.38 ±24.41)pg/mL, (11.63 ±4.05)pg/mL,(106.62 ±13.74)pg/mL,which were significantly higher than those of the control group [(32.32 ±3.04)pg/mL,(134.83 ±18.92)pg/mL,(9.26 ±3.35)pg/mL,(65.24 ±15.51 )pg/mL,t =4.905, 3.926,3.561,11.916,all P <0.05].The IL -17,18,32,KL -6 levels of group B were (92.68 ±13.25)pg/mL, (357.44 ±26.35)pg/mL,(50.10 ±9.88)pg/mL,(285.64 ±25.40)pg/mL,which were significantly higher than those of group A,the differences were statistically significant between the two groups (t =15.674,42.479,25.995, 45.293,all P <0.05 ).Conclusion The expression levels of IL -17,18,32 and lung adenocarcinoma antigen KL -6 are elevated with the increased severity of AECOPD patients.Therefore,the expression levels of these four indicators can be used to evaluate the severity of AECOPD patients.

Related Research on Traditional Chinese Medicine Syndromes and TNM Staging and Tumor Antigen in Primary Lung Cancer / 世界科学技术-中医药现代化

This article was aimed to study the relevance on traditional Chinese medicine (TCM) syndromes and TNM staging and tumor antigen in primary lung cancer, in order to provide theoretical supports for TCM prevention and treatment as well as medication guidance of primary lung cancer. Statistical data from 388 lung cancer patients were analyzed according to the relevance TCM syndromes, in order to find the relation between syndrome distribution of lung cancer and TNM staging and tumor antigens. The results showed that in TNM staging, the incidence of lung-yin deficiency syndrome in I stage was apparently higher than that in IV stage; the incidence of spleen-qi deficiency syndrome in IV stage was apparently higher than that in I stage; and there was no obvious difference in lung-qi deficiency syndrome, stasis obstructing lung collateral syndrome or lung-yin deficiency with fire-excess. The proportion of CEA in lung-yin deficiency with fire-excess syndrome was significantly higher than that in lung-yin deficiency syndrome, lung-qi deficiency syndrome, and stasis obstructing lung collateral syndrome. The proportion of abnormal increasing of NSE in lung-yin deficiency with fire-excess syndrome was significantly higher than other syndromes. The proportion of abnormal increasing of CYFRA21-1 in lung-yin deficiency with fire-excess syndrome and stasis obstructing lung collateral syndrome was significantly higher than that in lung-qi deficiency syndrome. It was concluded that there were certain relevance between TCM syndromes and TNM staging in lung cancer. Lung-yin deficiency syndrome, which existed in all stages of lung cancer, was the most obvious in the early stage. Spleen-qi deficiency syndrome was commonly seen in the advanced stage of lung cancer. There were certain relevance between different TCM syndromes and the abnormal increasing of tumor antigens including CEA, NSE and CYFRA21-1.

Anti-tumor Cytotoxicity of Allogeneic Neuroblastoma Tumor Antigen-loaded Dendiritic Cells / 대한혈액학회지

BACKGROUND: Despite of aggressive treatments, the long-term survival rate is about 30% in stage 4 neuroblastoma (NBL). Recently, dendritic cell (DC)-based immunotherapy is emerging as a promising tool in cancer treatment. But it is very difficult to get sufficient amount of autologous tumor as the source of tumor antigen in DC-based immunotherapy. The purpose of this study was to test whether DCs loaded with allogeneic NBL tumor antigens can prime effective anti-tumor immune responses. METHODS: Peripheral blood mononuclear cells (PBMCs) were differentiated into immature DCs in the presence of GM-CSF and IL-4. As the source of tumor antigens, human neuroblastoma cell lines, SK-N-MC, SK-N-SH, and IMR-32, were used after induction of apoptosis by UV irradiation. The immature DCs were loaded with apoptotic tumor cells, and then cultured with PBMCs for priming the tumor antigen-specific T lymphocytes. The tumor-specific cytotoxicity of T lymphocytes against NBL cells was analysed after coculture. RESULTS: Incubation of DCs with apoptotic tumor cells effectively loaded DCs with tumor antigens and induced maturation of DCs. The tumor antigen-challenged T lymphocytes effectively killed the NBL cells, which were used as tumor antigens. Furthermore, the T lymphocytes showed a broad ranged cytotoxicity to all of the NBL cell lines, which were not challenged as tumor antigens. CONCLUSION: This study showed that the apoptotic NBL tumor cells induced maturation of DCs and could be used as tumor antigens, and DCs loaded with apoptotic NBL tumor cells could induce effective anti-tumor specific cytotoxic T lymphocytes to allogeneic NBL tumors.

Tumor immunotherapy:progresses and trends / 中国肿瘤生物治疗杂志

New tumor antigens are continuously being discovered due to the improvement of immunologic techniques.Whether dendritic cells induce immune activation or immune inhibition after they capture tumor antigens depends on the danger signals(GM-CSF,MCP1,and HSP) or the inhibitory signals(TGF-?,IDO,and iNOS) released by tumor cells.Under the regulation of danger signals,dendritic cells activate Th1 immune response and eliminate tumors;under the regulation of inhibitory signals,they activate Th2 immune response and can not effectively eliminate tumors.Progress in tumor immunotherapy mainly is manifested by antibody-based therapy,T cell-based therapy,and tumor vaccine-based therapy.To day at least 7 antibodies have been confirmed effective when combined with chemotherapeutic agents in treatment of tumors.Despite of the progress made in antibody therapy,discovery of new targets,development of new antibodies,and expanding of the application scope to more tumors still need intensive research efforts.The clinical effects of T cell-based therapy have not been satisfactory;most tumor vaccine-based therapies are in phase Ⅰ and Ⅱ clinical trial,and the outcomes of few phase Ⅲ clinical trials are not satisfactory,leaving more work to be done for improvement.As we understand more about the roles of antibody in immune surveillance,it will help to make immunotherapy of tumors a promising strategy.

Zinc finger protein 216 up-expressed in hepatocellular carcinoma tissue and sera / 基础医学与临床

Objective To find antigens related with hepatocellular carcinoma(HCC).Methods Human Zinc Finger Protein 216(ZNF216) was identified by SEREX(serological analysis of recombinant cDNA expression libraries,SEREX).The 6His fusion protein of ZNF216 was expressed by bacteria and purified with a nickel affinity chromatography column.The level of anti-ZNF216 antibody in the sera was detected by ELISA,andZNF216 mRNA level in HCC tissue and its peripheral normal tissue was detected by RT-PCR.Results The level of anti-ZNF216 antibody in the sera of HCC patients was higher than that of healthy individuals.ZNF216 mRNA level in HCC tissue is evidently higher than peripheral normal tissue.Conclusion The over-expression of ZNF216 in the HCC sera and tissue indicates that ZNF216 perhaps plays a role in HCC.

Overexpression of Metastatic Tumor Antigen in Osteosarcoma: Comparison between Conventional High-Grade and Central Low-Grade Osteosarcoma / Journal of the Korean Cancer Association, 대한암학회지

PURPOSE: The metastatic tumor antigen (MTA) gene is a recently identified metastasis-associated gene which has implications in the signal transduction or regulation of gene expression. However, the expression of MTA in osteosarcoma and its potential relationship with metastasis have not been examined, forming the basis of this study. MATERIALS AND METHODS: We compared the expression levels of the MTA1 protein between 32 cases of high- grade osteosarcomas and 21 cases of low-grade osteosarcomas by immunohistochemistry. In addition, the mRNA expression levels of MTA1, 2, 3 in these osteosarcoma cell lines and control fibroblasts were evaluated by real-time quantitative PCR. RESULTS: MTA1 immunoreactivity was present in 81.25% of high-grade osteosarcoma specimens. Its expression was predominantly localized to the nucleus or cytoplasm of osteosarcoma cells. Thirteen (86.6%) of 15 patients who died of osteosarcomas displayed strong MTA1 expression. Both primary bone and pulmonary metastatic lesions exhibited MTA1 expression. All low- grade osteosarcomas were negative for MTA1 except for focal weak reactivity in two cases. The tested high-grade osteosarcoma cell lines showed marked amplification of MTA1 and MTA2 mRNA compared to control cells. CONCLUSION: These results suggest that MTA might be involved in the progression of high-grade osteosarcoma, particularly in hematogenous metastasis of osteosarcoma.

Urinary NMP22 and BTA tests as screening markers for bladder transitional cell carcinoma / 대한임상병리학회지

BACKGROUND: Urinary bladder cancer has been diagnosed by urine cytology and cystoscopy with biopsy. Recently, in vitro noninvasive diagnostic tests, measuring urinary nuclear matrix protein22(NMP22) and bladder tumor antigen(BTA), were introduced. We analyzed the usefulness of the NMP22 and BTA tests for diagnosing bladder cancer and compared those with voided urine cytology. MATERIALS AND METHODS: Single voided urine specimens were obtained from 27 patients with bladder cancer and 23 healthy volunteers. The urine specimens were assayed by enzyme immunoassay(NMP22, Matrietech(R), Newton, MA.) and latex immunoassay(BTA, Bard, USA). Urine cytology was performed in patients with bladder cancer. RESULTS: Mean urinary NMP22 level of patients with bladder cancer(144.6 U/mL) was significantly higher than those of normal controls(2.9 U/mL, P<0.01). The sensitivities were 89% and 74% for NMP22 and BTA tests, respectively, compared with 41% for voided urine cytology. The sensitivities of NMP22 and BTA tests were 88%, 63% at grade 1(G1), 82%, 73% at G2, and 100%, 88% at G3, respectively(P<0.01; NMP22, P=0.580; BTA). According to tumor stage, the sensitivities of NMP22 and BTA tests were both 79% at superficial, and 100% and 69% at invasive cancer, respectively(P=0.110; NMP22, P=0.678; BTA). The sensitivities of urine NMP22 and BTA tests combined with urine cytology were both 96%. In following of transitional cell carcinoma patients, agreement between urine cytology and BTA test was 75%(24/32). Among the various urologic disease, false positive rate for BTA test was 17%(8/47). CONCLUSION: Urinary NMP22 and BTA tests were more sensitive than voided urine cytology regardless of tumor grade and stage, so these noninvasive and simple tests can be used as screening tests for urinary bladder transitional cell carcinoma.

Clinical Significance of BTA Stat Test in the Diagnosis of Bladder Cancer / 대한비뇨기과학회지

PURPOSE: We compared the sensitivity and specificity of BTA stat test with those of voided urine cytology and bladder washing cytology in the detection of bladder cancer. MATERIALS AND METHODS: Voided urine samples were obtained from 114 persons and were tested for BTA stat test. Cytology was performed with the same urine of those who were suspected of having bladder cancer and those on follow-up after treatment of bladder cancer. Cytology reports of either class IV or V were considered positive. Cystoscopy and bladder washing cytology were performed subsequently. RESULTS: Cystoscopy revealed bladder cancer in 34 patients. Overall sensitivity of BTA stat test was 88% versus 41% of voided urine cytology (p<0.001). BTA stat test was more sensitive than bladder washing cytology in a subset of 24 patients by 88% to 58% (p<0.05). Specificity of BTA stat test was 74% in 39 persons who were either healthy (10) or had urologic diseases other than bladder cancer (29). Specificity was 61% versus 95% of voided urine cytology in 41 follow-up patients without gross evidence of recurrence(p<0.001). Four patients had both false positive BTA and cytology: 2 received TURB for recurrent bladder cancer 6 months later and the others showed repeated positive cytology without evidence of recurrence 3 and 6 months later. CONCLUSIONS: BTA stat test is superior to cytology (voided and washing) in detecting bladder cancer, but is not reliable enough to substitute cystoscopy. It may somehow allow some flexibility to a strict follow-up cystoscopy schedule in carefully selected cases. Longer follow-up is needed with false positive cases to determine whether BTA stat test is capable of predicting recurrence.

The Usefulness of Cytokeratin 7 and Colon Ovarian Tumor Antigen in the Differential Diagnosis of Primary and Metastatic Ovarian Tumors

Cytokeratin 7 has been known to be present in various types of human epithelial cells including the ovarian neoplasms, but not in colon cancers. The antibody to colon ovarian tumor antigen (COTA) has been introduced as a marker of colon and ovarian tumors. The aim of this study was to evaluate the usefulness of cytokeratin 7 and COTA in the differential diagnosis between ovarian primary and metastatic tumors. Nineteen primary ovarian epithelial tumors, seven metastatic carcinomas of the ovary from the stomach, three metastatic carcinomas of the ovary from the colon, one mucinous tumor of the ovary associated with a mucinous tumor of the appendix and pseudomyxoma peritonei, and nineteen colonic and twenty gastric adenocarcinomas were stained with monoclonal antibodies to cytokeratin 7 and COTA. The results are summerized as follows; In the primary ovarian tumors, 94.4% were positive for cytokeratin 7 and 50% were positive for COTA. In the primary colonic adenocarcinomas, 94.7% were negative for cytokeratin 7 and 68% were positive for COTA. In the metastatic ovarian tumor from the colonic adenocarcinomas, 100% were negative for cytokeratin 7 and positive for COTA. In the primary gastric adenocarcinomas, 40% were negative for cytokeratin 7 and 85% were negative for COTA. In the metastatic ovarian tumor from the gastric adenocarcinomas, 43% were negative for cytokeratin 7 and 14% were negative for COTA. From the results of this study, it could be concluded that in the differential diagnosis of primary ovarian tumors from metastatic colonic carcinomas, positive reaction for cytokeratin 7 suggests a primary ovarian tumor but a negative reaction for cytokeratin 7 and positive reaction for COTA suggest metastatic colonic carcinomas. The results of this study also reveal that cytokeratin 7 and COTA are not useful in the differential diagnosis of primary ovarian tumors from metastatic gastric carcinomas.

In vitro Proliferation and Cytotoxicity of PBMC Induced by Autologous Tumor Specific Antigen Costimulated with IL-2 / 中国肿瘤生物治疗杂志

To observe its proliferation and cytolytic activity in vitro induced by autologous soluble tumor antigen and IL-2, PBMC costimulated with TSA extracted from gastric tumor by biochemical procedure and IL-2 was cultured. The proliferation and cytotoxicity were evaluated by MTT method and the phenotype was analysed by APAAP method. TSA alone did not induce PBMC proliferation while TSA (10?g/ml) with IL-2 presented syngenic stimulating effect which was time and concentration dependent. The cytolytic unit of PBMC induced with IL-2/TSA was 86.3% vs 48.6% with IL-2 alone. The phenotypic measurement demonstrated that TSA enhanced CD25 and CD8 expression significantly. The observation offered experimental data for further research work about tumor activated killer(TAK) cells. The results indicated that TAK cells would be a new type of immunoactive cells in adoptive immunotherapy against tumor.

Study on the Antigens of Tumor FBL-3:I.Prediction of FBL-3 Antigen and Verification of Antigenicity of Synthetic Peptides / 中国肿瘤生物治疗杂志

T lymphocytes play a very important role in tumor immunity, which recognize tumor antigenic peptide presented by MHC molecules on the surface of tumor cells through T cell receptor ( TCR) . Cytotoxic T lymphocytes kill tumor cells after recognizing antigenic peptide in the cleft of MHC class I molecules. It is now generally accepted that peptides naturally presented by a given MHC class I molecule have a specific motif which is referred to as MHC class I allele-specific consensus motif and that synthetic peptide corresponding to the identified naturally presented antigens exhibit remarkable activity in inducing T-cell responses. FBL-3 is a transplantable Friend virus-induced leukemia of B6 (H-2b) origin,which can induce the CTL against FBL-3 by immunizing B6 mice with atenuated FBL-3.Seven peptides were predicted as candidates of FBL-3 antigenic peptides in the light of H-2Db specific peptide binding motif and gag gene sequence of Friend virus. The synthetic peptides, named gagl to gag7, were obtainted. The results showed that CTL specific to gag3 could be induced by in vivo immunizing B6 mice with gag3 in IFA, but a primary T cell response could not be induced by in vitro immuniztion with the peptides. gag3 and gag5 could be recognized by specific CTL to FBL-3,because the CTLs obviously killed target cells (EL-4) pulsed with gag3 or gag5. Immunization with gag3 and gag5 could not induce an immune response to protect the subsequent challenge of FBL-3 in B6 mice which could be induced by immunizing B6 mice with parental FBL-3 tumor cells. This indicates these 7 synthetic peptides may not be the same antigens of the FBL-3.

STUDIES OF MONOCLONAL ANTIBODIES TO SYNGENIC MOUSE LEUKAEMIA ASCITIC CLONE CELLS / 中国免疫学杂志

4 mouse hybridoma cell lines stea-dily secreting monoclonal antibodiesagainst surfaced antigens of mouseleukaemia cells were obtained byfusing mouse SP2/0 myeloma cellswith SW-1 mouse spleen cells im-mnized with viable leukaemia asci-tic clone-1(LAC-1)cells,The McAbwas found especially to bind onlywith LAC-1 cells but not with nor-mal SW-1 mouse thymocytes andConA stimulated thymocytes orot her mouse tumor cells includingL_(6565),L_(783),SRS,L_(7712)mouseleukaemia as well as the leukaemiavirus isolated from LAC-1 cellculture supernatant by ELISA.The McAb lost its binding abilityafter absorption with LAC-1 cells.All of the McAbs were of IgG2b sub-classes and did not show any cytoto-xicity to LAC-1 cells in the presenceof complement in vitro,but theydid block the specific cytotoxicityto the targets affected by LAC-1cells induced Tc in ~(51)Cr releaseassay.

Enhancing effect of IL-18 gene modification on the induction of antitumor immunity by antigen pulsed dendritic cells / 中国免疫学杂志

Objective:In order to study the antitumor immune response induced by antigen pulsed,IL 18 gene modified dendritic cells in vivo.Methods:①C57BL/6 mice were immunized twice subcutaneously by tumor antigen peptide pulsed,IL 18 gene modified dendritic cells(DC IL 18/mut1)(1?10 5 cells/mouse),then the NK activity and CTL activity were determined.②In block test,C57BL/6 mice were first immunized once 2?10 5 cells/mouse DC IL 18/mut1 subcutaneously,and then challenged by 5?10 5 3LL Lewis lung cancer cells/mouse with blocking different immune components by monoclonal antibody,the tumor growth were observed.Results:Specific CTL activity and NK activity could be induced most significantly in mice immunized with DC IL 18/mut1.The block test showed that CD4 +T,costimulating pathway,the production of IFN ? involved in the induction phase of immunization with DC IL 18/mut1,and CD8 +T?IFN ??NK cells involved in the effect phase but CD4 +T cells unnecessary.Conclusion:Immunization with DC msIL 18/mut1 could induce potent antitumor immune activity,whose mechanisms involved effective antigen presentation,increased CTL activity and NK activity,CD4 +?CD8 +T?NK cells incorporation,and the production of IFN ?.

Finding and identification of a novel HLA-A2-restricted CTL epitope derived fromthe tumor antigen MAGE-A3 / 中国免疫学杂志

To identify novel HLA-A2-restricted CTL epitopes derived from the tumor antigen MAGE-A3.Methods:The CTL epitope candidates were predicted by using the motif prediction method combined with the secondary anchor residues plot. It was established that the molecule model of CIL epitope candidates bound to the HLA-A2 molecule and of the HLA-A2-peptide complex by molecule modeling. Four selected candidates were assayed by the standard 51 Cr release assay to determine their abilities of inducing the generation of specific CTLs. Results: Among them, the pepnde MAGE-A3201-209 could effectively induce specific Oils and the CITs could lyse not only the melanoma cell line LB373-MEL but also the murine mastocytoma cell line genetically modified with the human HLA-A2 gene and pulsed with MAGE-A32oi.2cs ? Conclusion; MAGE-AS201-209 is a novel CTL epitope presented by HLA-A2. This study provides experimental basis for design and study of tumor therapeutic peptide vaccines based on the tumor antigen MAGE-A3.

A glycoprotein from plant(ZPP):study on tumor common antigen / 中国免疫学杂志

Objective:Tumor common antigen of an extract of plant and applying in early stage diagnosis for tumor were studied.Methods:Tumor cells and lymphocytes proliferate responses were determined by 3H-TdR intervening.Fresh tumor tissue from human transplant to mice,the survival rate of transplanted tumor was observed.DNA content of tumor cells was measured by flowcytometery.The chemical nature was analyzed by chromatography and measured by ultraviolet-spectrometer.Results:The extract of plant markedly stimulated the lymphocytes from tumor patients and atypical hyperplasia patient to proliferate,but failed to health persons(P

Preparation of SEREX-defined tumor antigens and preliminary study of their sero-reactivity / 中国免疫学杂志

Objective:To obtain tumor antigens for study of the sero activity in sera of normal subjects and tumor patients.Methods:Had cloned MY OVA 2,7 and 13 full length genes and expressed the fusion proteins in E.Coli.The proteins were characterized by SDS PAGE and Western Blot.Using bacterially synthesized and purified proteins,74 patients with different kinds of tumors and 13 healthy controls by dot blot were investigated.Results:Expressed fusion proteins at high level,reaching a yield at least 30% of the total bacteria protein.By using affinity chromatography and thrombin digestion,finally gained three purified proteins,which could be applied to serum screening.Dot blot results showed that auto antibodies against MY OVA 2 and MY OVA 7 were detectable in some of tumor and normal samples,while antibody against MY OVA 13 was only detected in tumor patients(5/74) and not detected in normal subjects(0/13).Conclusion:Tumor antigens prepared from genetic engineering can be adopted for effective seroscreening.

Autoantibodies:the early diagnostic biomarkers for tumors / 西安交通大学学报(医学版)

Tumor markers refer to the specific substances that exist in tumor cells themselves or are secreted by tumor cells. They can reflect the existence and growth of the tumor. The serum tumor biomarkers have been widely applied in tumor detection,but the detection of these markers is based on the tumor antigens,and thus has many inadequacies in tumor screening and diagnosis. In this paper,we reviewed autoantibodies as tumor biomarkers against self-antigens in vivo. This method is to examine the tumor autoantibodies by using the tumor antigens,and its specificity and sensitivity are superior to the traditional examination methods. Using autoantibodies to detect tumors would provide a new method for tumor screening and diagnosis.